Jupiter enters psychedelics space with $100M deal for PharmAla’s MDMA drug

Jupiter Neurosciences will pay $3.3 million upfront to Canada’s PharmAla Biotech for U.S. rights to an MDMA drug to treat neuropsychiatric disorders.